Screener
Protagonist Therapeutics PTGX Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 54,709 | 47,587 | 114,725 | 95,218 |
| Income (loss) from operations | 158,766 | (42,041) | 155,118 | (61,351) |
| Interest income | 6,429 | 7,406 | 12,305 | 14,979 |
| Other (expense) income, net | (81) | 36 | (28) | 118 |
| Income (loss) before income tax expense | 165,114 | (34,599) | 167,395 | (46,254) |
| Income tax expense | 2,265 | 172 | 763 | 172 |
| Net income (loss) | $162,849 | $(34,771) | $166,632 | $(46,426) |
| Net income (loss) per share, basic | $2.47 | $(0.55) | $2.54 | $(0.73) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's other income (expense)?
- Protagonist Therapeutics (PTGX) reported other income (expense) of -$81K in Q2 2026.
- How has Protagonist Therapeutics's other income (expense) changed year-over-year?
- Protagonist Therapeutics's other income (expense) decreased by 325.0% year-over-year, from $36K to -$81K.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Protagonist Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude